Tempus AI Posts First Adjusted EBITDA but Stock Still Faces Clouds

Tempus AI, Inc. (NASDAQ: TEM) celebrated a milestone in Q3 2025 by achieving its first positive adjusted EBITDA, signalling an important step toward profitability. Revenue surged around 84.7 % year‑over‑year to roughly $334 million, and the company lifted its full‑year revenue guidance to about $1.265 billion. However, the optimism is tempered by several caution flags. The reported positive EBITDA excludes significant costs—such as R&D, stock‑based compensation and the drag from the recent acquisition of Paige—and the company still posted a net loss of about $80 million in the quarter. Furthermore, the valuation remains sky‑high: at a market cap near $15.4 billion, TEM is trading at roughly ‑21.9× EV/EBITDA and ‑39.3× P/E, despite not yet generating sustainable cash‑flow. In short, while Tempus AI’s operational momentum and large total addressable market (TAM) in genomics and AI‑driven diagnostics are impressive, the premium valuation and lingering losses underpin why many analysts are advising hold rather than buy. #TempusAI #HealthcareAI #BiotechValuation #AdjustedEBITDA #SlimScan #GrowthStocks #CANSLIM